October 2025
1. SELIGMANN JF, Morton D, Elliott F, Handley K, et al
   Corrigendum to "Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population": [Ann Oncol 36 (2025) 520-528].
   Ann Oncol. 2025 Oct 9:S0923-7534(25)04703-9. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   September 2025
2. TIAN H, Zhang RX, Zhang D
   A Temporal Paradox in the Proposed Risk-Adjusted Surveillance Algorithm for Metastatic Colorectal Cancer.
   Ann Oncol. 2025 Sep 26:S0923-7534(25)04783-0. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   
3. SALAZAR R, Carmona-Bayonas A
   Toward risk-adjusted CT schedules in first-line metastatic colorectal cancer.
   Ann Oncol. 2025 Sep 23:S0923-7534(25)04780-5. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   
4. LEPAGE C, Phelip JM, Cany L, Barbier E, et al
   Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer.
   Ann Oncol. 2025 Sep 17:S0923-7534(25)04701-5. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   August 2025
5. GERMANI MM, Heinemann V, Rossini D, Fischer von Weikersthal L, et al
   Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO.
   Ann Oncol. 2025 Aug 19:S0923-7534(25)00921-4. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   
6. BAROT S, Liljegren A, Nordenvall C, Blom J, et al
   Incidence Trends and Long-Term Survival in Early-Onset Colorectal Cancer: A Nationwide Swedish Study.
   Ann Oncol. 2025 Aug 13:S0923-7534(25)00920-2. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   June 2025
7. HUANG YQ, Chen XB, Cui YF, Yang F, et al
   Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision.
   Ann Oncol. 2025 Jun 4:S0923-7534(25)00766-5. doi: 10.1016/j.annonc.2025.
   

   >> Share

   
   
8. RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al
   Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors.
   Ann Oncol. 2025;36:682-692.
   

   >> Share

   
   May 2025
9. WILLIAMS H, Fokas E, Diefenhardt M, Lee C, et al
   Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.
   Ann Oncol. 2025;36:543-547.
   

   >> Share

   
   February 2025
10. BARON D, Pace Loscos T, Schiappa R, Barbet N, et al
    A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.
    Ann Oncol. 2025;36:208-215.
    

    >> Share

    
    January 2025
11. SELIGMANN JF, Morton D, Elliott F, Handley K, et al
    Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.
    Ann Oncol. 2025 Jan 11:S0923-7534(25)00002-X. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    December 2024
12. MARTINEZ-CASTEDO B, Camblor DG, Martin-Arana J, Carbonell-Asins JA, et al
    Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.
    Ann Oncol. 2024 Dec 13:S0923-7534(24)04981-0. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
13. CANDIA L, Cervantes A, Martinelli E
    Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline.
    Ann Oncol. 2024 Dec 3:S0923-7534(24)04952-4. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
14. ANDRE T, Shiu KK, Kim TW, Jensen BV, et al
    Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.
    Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
15. BEEHUAT TAN I, Lui R, Yan K, Lam R, et al
    Investigating the 'liquid-solid interface' in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment-where do we draw the line?
    Ann Oncol. 2024;35:1067-1070.
    

    >> Share

    
    November 2024
16. DE WILT JHW, van der Kruijssen DEW, Koopman M
    Reply to Letter to the Editor "Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4" by Guzel et al.
    Ann Oncol. 2024 Nov 4:S0923-7534(24)04052-3. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
17. KATAOKA K, Mori K, Nakamura Y, Watanabe J, et al
    Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
    Ann Oncol. 2024;35:1015-1025.
    

    >> Share

    
    
18. BERCZ A, Park BK, Pappou E, Nemirovsky D, et al
    Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy.
    Ann Oncol. 2024;35:1003-1014.
    

    >> Share

    
    October 2024
19. GUZEL HG, Ilhan Y, Onder AH
    Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4.
    Ann Oncol. 2024 Oct 10:S0923-7534(24)04053-5. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
20. ROMESSER PB, Cercek A
    Optimizing Rectal Cancer Treatment: A Path Towards Personalization.
    Ann Oncol. 2024;35:831-835.
    

    >> Share

    
    
21. CONROY T, Castan F, Etienne PL, Rio E, et al
    Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
    Ann Oncol. 2024;35:873-881.
    

    >> Share

    
    
22. LIN ZY, Zhang P, Chi P, Xiao Y, et al
    Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.
    Ann Oncol. 2024;35:882-891.
    

    >> Share

    
    August 2024
23. CIARDIELLO D, Bielo LB, Napolitano S, Martinelli E, et al
    Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
    Ann Oncol. 2024 Aug 28:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334
    

    >> Share

    
    
24. ROS J, Matito J, Villacampa G, Comas R, et al
    Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552].
    Ann Oncol. 2024 Aug 12:S0923-7534(23)00796-2. doi: 10.1016/j.annonc.2023.
    

    >> Share

    
    July 2024
25. BIONDO S, Frago R, Kreisler E
    Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
    Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
26. CECCHINI M, Sundar R
    Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta (POLE/POLD1)-altered colorectal cancer.
    Ann Oncol. 2024;35:582-584.
    

    >> Share

    
    June 2024
27. VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al
    Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    May 2024
28. AMBROSINI M, Rousseau B, Manca P, Artz O, et al
    Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    
29. BRENNER H, Niedermaier T, Hoffmeister M
    Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
    Ann Oncol. 2024;35:476-477.
    

    >> Share

    
    April 2024
30. KELSEN D, Ben-Aharon I, Gordon N
    Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
    Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    February 2024
31. LASKAR RS, Qu C, Huyghe JR, Harrison T, et al
    Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
    Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share